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Summary 
Drug resistance in Mycobacterium tuberculosis is an increasing global problem. Drug 
resistance is mostly caused by single nucleotide polymorphisms (SNPs) within the bacterial 
genome. This observed increase in global incidence of drug resistant tuberculosis (TB) has 
sparked the search for new anti-TB drugs and the repurposing of drugs that are currently used 
against other organisms or species of mycobacteria. One such repurposed drug, clofazimine 
(CFZ), is currently used for the treatment of leprosy, caused by Mycobacterium leprae. The 
mechanism of action of CFZ is not clear, but it is hypothesized that CFZ is reduced by a 
mycobacterial type II NADH oxidoreductase (NDH-2). The reduction of CFZ drives the 
production of reactive oxygen species (ROS) which is toxic to the pathogen. The aim of this 
study was to elucidate the mechanism of CFZ resistance. Towards this aim, spontaneous in 
vitro CFZ resistant mutants were selected, characterized and whole genome was used identify 
SNPs which may cause CFZ resistance. Mutations were identified in a transcriptional 
regulator encoded by Rv0678, fatty-acid-AMP ligase, or FadD28 (Rv2941) and glycerol 
kinase or GlpK (Rv3696c). Mutations in Rv0678 have previously been shown to play a role in 
both CFZ resistance and bedaquiline (BDQ) cross-resistance, while no link has been found 
between CFZ resistance and mutations in fadD28 and glpK. The novel, non-synonymous 
SNP identified in Rv0678 resulted in the replacement of an alanine residue with threonine at 
codon 84, which is located in the DNA binding domain. Virtual modelling of the mutated 
Rv0678 protein showed that the A84T mutation may influence DNA binding, possibly due to 
its proximity to the DNA binding domain. This mutation caused a change in hydrophobicity, 
which may influence binding to DNA. Previous studies showed that mutations in Rv0678 
resulted in the upregulation of mmpL5, a putative efflux pump. However, the mechanism 
whereby CFZ resistance occurs via increased abundance of this efflux pump in the cell wall 
is not clear and needs further investigation. The cross-resistance between CFZ and BDQ, 
caused by mutations in Rv0678, is of concern and may influence the planning of anti-TB drug 
regimens for the future. The roles of the other two mutations identified in this study in CFZ 
resistance is also not clear and requires further investigation. Finally, the findings of this 
study support the role of Rv0678 in CFZ resistance thereby suggesting that this gene could be 
useful as a diagnostic marker to test for CFZ resistance in clinical isolates. 
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Opsomming 
Middelweerstandigheid in Mycobacterium tuberculosis is 'n wêreldwye toenemende 
probleem. Middelweerstandigheid word meestal veroorsaak deur enkel nukleotied 
polimorfismes (SNPs) in die bakteriële genoom. Hierdie toename in middelweerstandige 
tuberkulose (TB) het gelei tot die soektog na nuwe anti-TB-middels en die alternatiewe 
aanwending van middels wat tans teen ander organismes of spesies van mikobakterieë 
gebruik word. Een so 'n alternatiewe middel, clofazimine (CFZ), word tans gebruik vir die 
behandeling van melaatsheid wat veroorsaak word deur Mycobacterium leprae. CFZ se 
meganisme van werking is nie duidelik nie, maar dit word vermoed dat CFZ gereduseer word 
deur 'n mikobakteriële tipe II NADH oksidoreduktase (NDH-2). Die reduksie van CFZ dryf 
die produksie van reaktiewe suurstof spesies wat giftig is vir die patogeen. Die doel van 
hierdie studie was om die meganisme van CFZ weerstandigheid te ondersoek. Om hierdie 
doel te bereik was spontane in vitro CFZ weerstandige mutante gekies, gekarakteriseer en 
heel genoom volgorde bepaling is gebruik om SNPs te identifiseer wat CFZ weerstandigheid 
veroorsaak. Mutasies in Rv0678, 'n transkripsie reguleerder, vetsuur-AMP ligase, of FadD28 
(Rv2941) en gliserol kinase of GlpK (Rv3696c) geïdentifiseer. Dit is al voorheen gevind dat 
mutasies in Rv0678 ‘n rol speel in beide CFZ weerstandigheid en bedaquiline (BDQ) kruis-
weerstandigheid, terwyl geen verband gevind is tussen CFZ weerstandigheid en mutasies in 
fadD28 en glpK nie. Die nuwe, nie-sinonieme SNP, geïdentifiseer in Rv0678 het gelei to die 
vervanging van 'n alanien aminosuur met treonien by kodon 84, wat geleë is in die DNS 
bindings domein. Virtuele modellering van die gemuteerde Rv0678 proteïen het getoon dat 
die A84T mutasie DNS binding moontlik kan beïnvloed, as gevolg van sy nabyheid aan die 
DNS bindings domein. Hierdie mutasie veroorsaak 'n verandering in die hidrofobiese natuur, 
wat DNS binding kan beïnvloed. Vorige studies het getoon dat mutasies in Rv0678 lei tot die 
opregulering van mmpL5, 'n waarskynlike uitvloei pomp. Die meganisme waardeur CFZ 
weerstandigheid veroorsaak, deur ‘n groot aantal van hierdie uitvloei pompe in die selwand, 
is nie duidelik nie en moet verder ondersoek word. Die kruis-weerstandigheid tussen CFZ en 
BDQ, wat veroorsaak word deur mutasies in Rv0678, is van belang en kan die beplanning 
van anti-TB middel behandeling vir die toekoms beïnvloed. Die rolle van die ander twee 
mutasies, wat in hierdie studie geïdentifiseer is, in CFZ weerstandigheid is ook nie duidelik 
nie en vereis verdere ondersoek. Ten slotte, die bevindinge van hierdie studie steun die rol 
van Rv0678 in CFZ weerstandigheid en dit dui daarop dat hierdie geen gebruik kan word as 
'n diagnostiese merker om vir CFZ weerstandigheid te toets in kliniese isolate.  
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Chapter 1 
General Introduction 
1.1. Background 
The M. tuberculosis genome undergoes spontaneous mutations and drug resistance clones are 
selected during monotherapy (1), necessitating the use of a multi-drug regimen. The current 
multi-drug regimen consists of a two month intensive phase of therapy, followed by a four 
month continuation phase. Drugs used during the intensive phase include isoniazid (INH), 
rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA), while the drugs used in the 
continuation phase only consist of INH and RIF. These four drugs are considered first line 
drugs (Figure 1.1), but when RIF resistance is detected, the regimen is adapted appropriately 
to include second line drugs, such as amikacin (AMK), kanamycin (KAN), and ethionamide 
(ETH) (2). 
Table 1.1: First and second-line drugs used in the TB treatment regimen. 
 
Treatment outcome of patients with resistance are poor (3–5) and are often associated with 
acquisition of additional resistance. Most recently, cases resistant to all available drugs have 
been reported (6). This increase has initiated the search for new drugs and repurposing of 
drugs used to treat other infections (7, 8). Although major investments are made in the 
development of new drugs, only a few drugs reach the market, such as bedaquiline (BDQ), a 
drug with a novel target within M. tuberculosis. This is the first novel drug to be approved by 
the Food and Drug Administration (FDA) in 40 years. According to the Working Group on 
New TB Drugs; various new anti-TB drugs, as well as repurposed drugs, are currently in 
clinical trials against TB.  
•Isoniazid 
•Rifamipicin 
•Ethambutol 
•Pyrazinamide 
First Line Drugs 
•Fluoroquinolones (Moxifloxacin,  Ofloxacin, and 
Levofloxacin) 
•Aminoglycosides (Kanamycin and Amikacin) 
•Thioamides 
•Pyrazinamide 
•Terizidone 
Second Line Drugs 
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It is important to establish the potential risks for drug resistance against the drugs that pass 
these clinical trials. Uncovering possible resistance mechanisms will assist the development 
of rapid and efficient diagnostic tests for the new or repurposed drugs.  
An example of a drug currently being repurposed for drug-resistant TB is clofazimine (CFZ).  
It belongs to the riminophenazine structural family and was developed for TB treatment (9), 
but the side effects of gastro-intestinal irritation, eosinophilic enteritis and blue-red skin 
discolouration led to the discontinued use of CFZ against TB. CFZ is currently used against 
leprosy, and it is rare that drug resistance arises (10). The bactericidal/static activity of CFZ 
against M. leprae is high, while the  activity against M. tuberculosis has shown promise in  in 
vitro and murine models (11).  
 
Figure 1.1: A schematic represenation of CFZ competing with menaquinone (MQ) for reduction 
by NDH-2 in M. smegmatis. Reduction of MQ forms part of the electrons transport chain (ETC) in 
the organism. The reduction of CFZ leads to the formation of reactive oxygen species (ROS). 
(Adapted from (12)) 
 
The mechanism of action of CFZ against M. tuberculosis has not been established, but it has 
been suggested that it may play a role in redox reactions. Reduction of CFZ was reported in 
1957, when M. tuberculosis grown in aerobic conditions in the presence of CFZ turned 
reddish in colour, and when switched to anaerobic growth conditions returned to colourless 
(12). The Yano et al. (2011) study showed that mycobacteria treated with CFZ results in the 
production of reactive oxygen species (ROS) through a cyclical pathway fuelled by O2 and 
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NADH (12). The continual production of NADH by fatty acid β-oxidation and/or the citric 
acid cycle will drive the cycle, driving the production of ROS. It has been shown in M. 
tuberculosis and M. smegmatis that a mycobacterial type II NADH oxidoreductase (NDH-2) 
“is the only oxidoreductase mediating the transfer of NADH electrons/H+ to the respiratory 
chain” (12). This may explain why it was difficult generate CFZ resistant M. tuberculosis in 
vitro (12). 
At the start of this study not much was understood about the mechanism of resistance against 
CFZ in vitro or in vivo. 
1.2. Problem Statement 
The mechanism(s) whereby M. tuberculosis develops CFZ resistance is poorly understood. 
1.3. Hypothesis 
Mutations which cause CFZ resistance and do not severely affect growth phenotype in vitro 
will predominate in CFZ resistant clinical isolates. 
1.4. Overall Aim 
To identify mutations causing CFZ resistance. 
1.4.1. Specific Aim 1 
To generate CFZ mono-resistant mutants in vitro. 
1.4.2. Specific Aim 2 
To identify phenotypic differences between the progenitor and the CFZ mono-resistant 
mutant through growth analysis, cell and colony morphology and minimum inhibitory 
concentration determination. 
1.4.3. Specific Aim 3 
To identify genomic differences between the progenitor and the CFZ mono-resistant mutant.  
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Chapter 2 
Literature Review 
Preclinical and Clinical Anti-Tuberculosis Drug Development 
2.1. Introduction 
Prior to the antibiotic era, during the early 1900’s, tuberculosis (TB) was a major cause of 
death, especially during World War II within concentration camps (13, 14). Mathematical 
models indicate a steady decline in the incidence of respiratory TB, before the discovery of 
streptomycin (STR) in 1944 (15). It is suggested that this decline was due to the development 
and improvement of health care facilities (16, 17). Importantly the discovery and 
implementation of STR in the TB treatment regimen resulted in a noticeable decrease in 
mortality rates of TB patients (17).   
The first cases of TB mortality due to the development of STR resistant M. tuberculosis 
strains were reported in 1948 by the British Medical Research council (18). Alternative 
treatment options for patients with STR resistant TB included the administration of para-
aminosalicylic acid (PAS), as it was shown that STR resistant M. tuberculosis was sensitive 
to PAS (19). The discovery of STR and PAS was followed by isoniazid (INH) (20), 
pyrazinamide (PZA) (21) and cycloserine (CYC) in 1952 (22). Development of additional 
drugs followed slowly until 1996 (Table 2.1), but renewed research focus and funding has led 
to the development of several new promising candidates that have not been approved for use 
by humans (22). 
To prevent the emergence of drug resistance, current regimens employ multiple drugs to 
enhance killing via different targets and mechanisms of action. The standard drug therapy 
regimen for drug susceptible TB, is divided into two phases. The first phase is a two month 
intensive phase treatment with INH, rifampicin (RIF), PZA and ethambutol (EMB) (Table 
2.1). This is followed by a continuation phase of treatment with INH and RIF for four 
months. Upon identification of drug resistance to the first-line drugs, second-line drugs 
(Table 2.1) are administered.  
Directly Observed Therapy – Short Course (DOTS) was the first strategy implemented 
globally to control the transmission of TB (23). DOTS was based on five key elements; (i) 
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commitment from the government to maintain TB control, (ii) use of sputum-smear 
microscopy to diagnose patients, (iii) observation of treatment, (iv) a functional supply of 
drugs, and (v) a standardised system to record and report the results (23, 24).  
Table 2.1: Information regarding the current drugs used against M. tuberculosis. 
FASI, fatty acid synthase I; ETH; ethionamide; KAN: kanamycin; CAP: capreomycin AMK: amikacin; 
RFB, rifabutin; LEV, levofloxacin; OFL: ofloxacin; GAT: gatifloxacin; MOX: moxifloxacin 
 
In 2006, the World Health Organization (WHO) launched the Stop TB Strategy. This strategy 
aimed to (i) expand and enhance the DOTS strategy, (ii) address challenges such as TB/HIV 
and multidrug-resistant tuberculosis (MDR-TB), (iii) strengthen health systems, (iv) involve 
all care providers, (v) empower TB patients and communities, and (vi) enable and promote 
Drug 
Year 
Discovered 
Target Mechanism of Action 
Resistance 
Causing 
Mutation 
References 
First Line 
STR 1944 16S rRNA Protein translation disruption rrs, rpsL (25) 
INH 1952 InhA Inhibit mycolic acid 
synthesis  
inhA, inhA 
promoter,  
katG, ndh, 
ahpC, kasA 
(26, 27) 
PZA 1952 RpsA and 
FASI pathway 
Blocks trans-translation  pncA, rpsA (28) 
EMB 1961 Arabinosyl 
transferase 
Inhibit cell wall 
arabinogalactan synthesis 
embB (29, 30) 
RIF 1963 RNA 
polymerase 
Inhibit transcription  rpoB (27, 31) 
Second Line 
CYC 1952 D-alanine 
ligase 
Inhibit D-alanine racemase 
and D-alanyl-D-alanine 
synthetase 
cycA 
(suspected) 
(32, 33) 
ETH 1956 InhA  Inhibit mycolic acid 
synthesis 
ethA, ethR, 
inhA and  
inhA 
promoter 
(34) 
KAN
 1957 16S rRNA Inhibit protein transcription rrs (29) 
CAP
 1963 16S rRNA Inhibit protein transcription tlyA (29) 
AMK 1972 16S rRNA Inhibit protein transcription rrs (29) 
LEV
 1986 DNA gyrase & 
DNA 
topoisomerase 
Inhibit DNA gyrase gyrA, gyrB (35) 
PAS 1944 Unknown Unknown thyA  
OFL 1982 DNA gyrase & 
DNA 
topoisomerase 
Inhibit DNA gyrase (36) gyrA, gyrB (36) 
GAT 1992 DNA gyrase & 
DNA 
topoisomerase 
Inhibit DNA gyrase gyrA, gyrB (37) 
MOX 1996 DNA gyrase & 
DNA 
topoisomerase 
Inhibit DNA gyrase gyrA, gyrB (37) 
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TB research (38). The subsequent implementation of the DOTS-Plus strategy aimed to 
control MDR-TB by subjecting suspect MDR-TB patients to drug susceptibility tests (DSTs), 
followed by treatment with second line drugs if the MDR-TB status was confirmed. Since the 
implementation of DOTS and the Stop TB strategy, in the mid-1990s, 56 million people have 
been successfully treated, saving 22 million lives (2).  
However; this has not prevented the development of MDR-TB and extensively drug-resistant 
TB (XDR-TB). M. tuberculosis is classified as MDR-TB when the strain is resistant to at 
least two of the first-line anti-TB drugs INH and RIF. In the case of XDR-TB, the isolate is 
resistant to INH and RIF in addition to any fluoroquinolone and at least one of the injectable 
drugs; amikacin (AMK), capreomycin (CAP) and kanamycin (KAN) (39). The emergence of 
drug resistance negatively influences the control of TB and thereby emphasizes the need for 
the development of new anti-TB drugs and treatment regimens.  
The need for new drugs or re-evaluation of existing drugs is fuelled by the increasing 
emergence of drug resistant TB and the lengthy treatment duration. Shorter drug treatment 
would help to reduce non-compliance, thus positively influencing TB control. Few studies 
focus on repurposing drugs, exceptions include fluoroquinolones that were originally used 
against other bacteria are now used as in TB treatment and CFZ which is currently being re-
evaluated to be used against drug resistant TB. This review will describe current drug 
development strategies; highlight the advantages and limitations of these approaches, and 
their application in the identification of potential drug targets and compounds.  
2.2. Drug Development 
 
Figure 2.1: A summary of the drug development process. The drug development process is 
divided into three phases, starting with preclinical development, and if a drug is identified during this 
step it moves on to clinical trials. If the drug passes these trials it is filed and approved by the Food 
and Drug Administration (FDA) Vol: volunteers 
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The development of a new drug is a lengthy process, illustrated in Figure 2.1. A limited 
number of compounds complete all the mandatory steps and stringent quality control 
measures for pre-clinical and clinical implementation. Potential anti-TB compounds should 
(i) target actively replicating cells as well as dormant and persister cells, (ii) have novel 
targets to combat MDR- and XDR-TB, (iii) shorten therapy time by being more potent, (iv) 
have no negative interactions with other anti-TB drugs and (v) should be compatible with 
anti-retroviral treatments, since many patients are HIV co-infected (40). 
2.2.1. Preclinical Drug Development 
 
Figure 2.2: Two preclinical drug development approaches. During A which is the target-based 
approach, the target is identified and validated, and then the compound is identified through 
biochemical assays, followed by further drug development. B is phenotype-based, where the 
compound is identified when it has the desired phenotypic effect, and it is developed further from 
there. 
 
Preclinical drug development is categorized into two approaches. The first is a phenotype-
based approach (forward chemogenomics) (Figure 2.2B), where the effects of new 
compounds are tested on the bacterium to find the desired phenotype. This is followed by 
target identification and validation (Figure 2.2), to understand the mechanism of action. The 
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second is a target-based approach (reverse chemogenomics) (Figure 2.2A), starting with 
identification and validation of protein and nucleic acid drug targets, followed by assays to 
search for candidate compounds. Mechanisms of actions studies will follow to eliminate 
redundancy in targets. Here the different steps will be described following the target-based 
order of events, but would be applicable (in reordered sequence) to the phenotype-based 
approach. 
2.2.1.1. Target Identification 
Identification and validation of a new drug target within the bacterium is very important since 
the target itself determines the efficacy of the new drug. A biological response that can be 
measured in vivo and in vitro should be observed when the potential compound is able to bind 
to the target. A good drug target will form part of an essential pathway within the bacterium, 
where the inhibition of its activity or disruption of its function will lead to the death of the 
bacterium. The new drug should have high specificity and affinity for the target. The drug 
must be efficient, meet the commercial and clinical needs, and must preferentially not elicit 
adverse effects in the host. The target should be novel to avoid the chance of cross-resistance 
between a new drug candidate and currently used drugs. 
Different approaches can be used to identify new drug targets within the bacterium, such as 
random mutagenesis where the significance of a metabolite for bacterium survival is 
determined. The random mutagenesis approach has been used efficiently for the identification 
of genes that affect virulence or growth of M. tuberculosis when the gene is disrupted (41, 
42). An example of random mutagenesis used for M. tuberculosis is transposon site 
hybridisation (TraSH), which investigates the essentiality of genes under different conditions 
(42). 
Another approach is compound identification where the effect of a compound on the 
bacterium is determined; subsequently the compound’s mode of action is determined. These 
compounds can come from either natural products or chemical libraries. After identifying a 
potential compound by minimum inhibitory concentration (MIC) in media with different 
carbon sources, the compound is further characterized by mutation frequency determination 
and subsequent mutant generation. During this approach a compound’s target is identified 
using chemogenomics, which includes drug resistant isolates undergoing DNA sequencing, 
whole transcriptome analyses and macromolecular synthesis of DNA, protein, RNA, fatty 
acids and peptidoglycan being assayed (43).  
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There are numerous criteria that have to be overcome following the identification of a crucial 
drug target. These include the following; i) the metabolite, transcribed by the target, must be 
required for infection of the host, not only made during certain disease states, ii) the 
bacterium should not be able to procure the metabolite from the host and iii) the metabolite 
should not be synthesised through other pathways to supplement the loss of the metabolite 
within the bacterium (43, 44). Genetic analyses are not able to provide all the necessary 
insight regarding the need a bacterium has for a particular metabolite. Other techniques which 
will help determine the necessity of the metabolite, includes systems biology, imaging in vivo 
and in vitro, metabolic modelling and profiling the cell content of the bacteria (45–48). 
2.2.1.2. Target Validation 
Different models exist to validate a drug target, ranging from in vitro culture-based models to 
in vivo modulation in disease patients. For example PA-824, a nitroimidazopyran, was tested 
in vitro using MDR-TB clinical isolates and in vivo using a murine model for infection, 
displaying high activity against M. tuberculosis (49). Using multiple validation techniques 
increases the confidence of the observed outcome. Different validation techniques include the 
use of monoclonal antibodies, antisense technology and small interfering RNA (siRNA). By 
using a variety of tools the cellular function of the target is evaluated and validated before 
investing and committing to screening potential hits. 
Monoclonal antibody validation can occur in vitro, where the antibody sequences are selected 
from a variable immunoglobulin region complementary DNA (cDNA) library, or in vivo, 
where host animals are immunised and hybridoma techniques are used to screen for the 
monoclonal antibodies (50). During antisense validation an antisense RNA oligonucleotide 
construct is delivered into the cell and the effects on messenger RNA (mRNA) expression 
measured. In the case of ilvD, which plays a role in isoleucine and valine biosynthesis in M. 
tuberculosis, it was found that after the addition of a plasmid with an antisense mRNA 
oligonucleotide the growth of M. tuberculosis in the lungs decreased noticeably in a murine 
model (51).  
It is important to select the right model, since previous studies have shown that different 
models may have different results. For example, metronidazole (MTZ) is able to kill M. 
tuberculosis under in vitro hypoxic conditions in rabbits but not under aerobic conditions 
(52). However, MTZ is ineffective in killing off M. tuberculosis infections in guinea pigs and 
mouse models (53, 54). While the administration of MTZ for two months to M. tuberculosis 
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infected macaques was as effective as a combination treatment of INH and RIF in preventing 
reactivation of a latent infection (55). 
2.2.1.3. Hit Discovery 
A hit is defined as a compound that exerts the preferred activity during compound screening 
and retesting (56). Compounds that have the potential to become hits are from different 
origins, including antibiotics that occur naturally, the synthesis of novel chemical compounds 
and the repurposing of existing drugs used against other bacteria. 
Natural drug discovery, where the compounds already exist within nature, started with 
penicillin discovery by Alexander Fleming in 1929 (57, 58). Since then it has been the 
cornerstone of novel drug discovery (59). Currently, the marine environment is a major 
source of natural antibiotics, compounds are isolated from bacteria, fungi and sponges (60).  
Compounds can be chemically synthesised and altered to design a successful hit, using 
techniques such as focused screening. 
The assays used to screen the identified compounds are normally cell-based, with nuclear 
receptors, ion channels and membrane receptors as drug targets. The other are biochemical 
assays which are used with enzyme and receptor targets, but often it merely measures the 
affinity of a test compound for the target protein. Assays are developed with certain 
requirements in mind, i.e. the relevant pharmacokinetics, reproducibility, low cost, high 
quality and the effects the compounds have in the assay (56). Table 2.2 illustrates the 
preclinical drug development sequence from hit discovery through to lead optimization. 
The carbon sources used during assays may play a role in the targets identified as viable 
candidates. When M. tuberculosis is grown in vitro the carbon sources used in the media are 
not the same as that available in vivo (61). An example was where an in vivo study identified 
isocitrate lyase (ICL) as a viable target in M. tuberculosis; while in vitro ICL is unnecessary 
for the survival of the bacterium (62). This study showed ICL chemical inhibition was 
dependent on propionate (C3) and polyoxyethylene sorbitan monolaurate (C12), while 
glycerol and glucose restored the growth of M. tuberculosis (62). 
The most recently approved anti-TB drug, bedaquiline (BDQ) (formerly TMC207 and 
R207910) was discovered during a whole cell assay, using Mycobacterium smegmatis as the 
test organism (63). A whole cell assay was preferred since it enables the assessment of 
multiple targets within the bacterium. BDQ, part of a chemical class diarylquinolines, showed 
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the most potent inhibition of M. tuberculosis, by inhibiting the bacterial ATP synthase (63). 
After being described for the first time in 2005, the drug was approved as an anti-TB drug in 
2012 by the Food and Drug Administration (FDA).  
Table 2.2: The target-based preclinical drug development sequence. 
Hit Discovery Hit Series Determination Hit-to-Lead Lead Optimization 
 HTS 
 Focused screening 
 Fragment screening 
 Virtual screening 
 Physiological 
screening 
 NMR 
Hits grouped according to 
SAR 
 Hit fragmentation 
 Bioisosteric replacement 
 Hit evolution 
 Ames test 
 Irwin’s test 
 Dose linearity 
 High-dose 
pharmacology 
 PK/PD studies 
 Pharmacokinetic 
repetitive dosing 
 Profiling drug 
induced metabolic 
processes 
One of the routes that can be followed during drug development, starting with hit discovery, followed by 
hit series determination, hit-to-lead and finally lead optimization. After passing all these steps, the drug 
goes through to clinical trials. HTS, high throughput screening; NMR, nuclear magnetic resonance and 
SAR, structure-activity relationship. 
 
High Throughput Screening 
Large numbers of compounds can also be screened using high throughput screening (HTS) 
where the compounds are analysed using a 384 well plate (64). To select which compounds 
to include during the screening, a database of compounds is initially screened for potency 
against M. tuberculosis. The compounds that show possible interaction are further filtered 
using Lipinski’s rule of five; discarding the compounds with a molecular weight of more than 
500, more than five donors of hydrogen bonds, with a lipophilicity value less than five and 
more than 10 possible hydrogen accepting atoms that could form hydrogen bonds (65).  A 
study, done in 2012, investigated 20 000 compounds using HTS (66). As expected, from 
these 20 000 compounds, only two were found to be effective against M. tuberculosis  as well 
as adhered to Lipinski’s rule of five. One of these compounds (a benzimidazole) targets 
mycobacterial membrane protein large 3 (MmpL3), which is a putative cell wall mycolic acid 
transporter (66). The other drug is a nitrotriazole which targets the decaprenylphosphoryl-β-
D-ribose 2’-epimerase (DprE1), which is required in cell wall biosynthesis (66).  
Identification of potential novel drug compounds within a large amount of compounds can be 
supported with visual assistance, for example a high-content screen (HCS). A HCS is where 
an ArrayScan™ System is combined with reagents that are fluorescence-based to determine 
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the roles targets play cell functions (67). During a HCS screen, of 57 000 small molecules, 
135 compounds were found to be active against M. tuberculosis and displayed no toxicity to 
the host cell (68). Dinitrobenzamide derivatives (DNB) which showed high activity against M 
tuberculosis were also found to be effective against XDR-TB (68). M. tuberculosis treated 
with DNB demonstrated the inhibition of arabinogalactan and lipoarabinomannan formation, 
which can be attributed to the inhibition of decaprenyl-phospho-arabinose synthesis catalysed 
by decaprenyl-phosphoribose 2’ epimerase DprE1/DprE2 (68). 
Another approach is a luciferase assay which measures the transcription of the iniBAC operon 
(69, 70). The iniBAC operon is expressed when drugs are administered to the mycobacterium, 
inhibiting cell wall biosynthesis (69, 70). Potential compounds active against M. tuberculosis 
cell wall biosynthesis can be identified through measuring the transcription of the iniBAC 
operon. This will also enable the detection of possible cross-resistance between currently 
used drugs and the potential compounds that both act on cell wall biosynthesis. 
Recent advances in liquid chromatography - mass spectrometry (LC-MS) has enabled its use 
in HTS. LC-MS can be used to determine if a potential compounds can be metabolised by the 
bacterium (71). The compound should not be metabolised by the bacterium, as this would 
enable the bacterium to survive treatment with the compound. 
Focused Screening 
Another technique used is focused screening where structures that bear similarity to 
previously identified compounds are screened against the target (Figure 2.3) (56). Click 
chemistry can be defined as joining small units, comprising of a few chemical elements, 
through heteroatom links (C-X-C) to form larger oligomers (72). Following this strategy, a 
small focused library of 1,2,3-triazoles was designed through click chemistry, and the 
compounds were tested against M. tuberculosis (73). According to M. tuberculosis H37Rv 
MIC tests one of the compounds was five times more active than econazole but equal to RIF, 
the two control drugs used in the study, suggesting that this compound may be more effective 
than the existing drugs (73). 
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Figure 2.3: Schematic representation of the focused screening technique. Structures that are 
similar to the original hit are tested against the drug target. Compounds that bind to the target are 
identified as hits. 
 
Fragment Screening 
The fragment screening method consists of three different approaches; virtual screening, 
nuclear magnetic resonance (NMR) and physiological screening (74). Fragment screening is 
where compounds, with little complexity (low mM activity), are used for larger molecule 
building blocks (75).  
Virtual Screening 
Virtual screening is made possible through the use of X-ray crystallography. X-ray 
crystallography uses the structure of a protein with a characterised ligand which serves as a 
base for the identification of compounds that will interact with the protein (Figure 2.4). The 
biggest disadvantage of virtual screening is that molecular level drug-receptor interactions are 
too complex for in silico hit discovery to be reliable (76). For example, a database containing 
over 500 000 compounds was virtually screened, in an attempt to find ATP 
phosphoribosyltransferase (HisG) inhibitors. By using the FlexX and GOLD docking 
algorithms several compounds were found to have 4-6 µM enzyme inhibition activity (Ki) 
against HisG, but further experimental procedure, using whole cell assays, were necessary to 
identify the one compound that was active against M. smegmatis  (77).  
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Figure 2.4: The virtual screening process. Structures that are similar to a known ligand which binds 
to a target is screened in silico to identify potential hits. 
 
Nuclear Magnetic Resonance 
Magnetic nuclei have different energy levels at different nuclear-spin states when placed in a 
magnetic field. By applying radio-frequency radiation these magnetic nuclei are enabled to 
switch between the different energy states, helping to determine the NMR properties of each 
molecule (78). Small compounds are screened by exposing them to known crystals or NMR 
protein target structures to identify hits that bind the best (Figure 2.5), but have a low mM 
activity (78). Hits from NMR screening are subsequently used as building blocks for larger 
molecules (78).  
 
Figure 2.5: Nuclear magnetic resonance. Analogues of small molecules are tested against the target 
to identify the small molecules that have better affinities for the target. The small molecules with the 
best affinities are used as building blocks for larger molecules which become hits. 
 
Examples of drugs identified using NMR are the new antimicrobial chemotypes identified in 
plants, hyperenone A and hypercalin B. Hyperenone A has a growth inhibiting effect on 
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MurE from M. tuberculosis H37Rv (79). There are constant efforts to find inhibitors of Mur 
enzymes which are essential in the biosynthesis of peptidoglycans, an important component 
in the M. tuberculosis cell wall (80). 
Physiological Screening 
Physiological screening, displayed in Figure 2.6, is tissue-based where drug effects are 
determined at a tissue level, rather than cellular or subcellular (56). A clofazimine (CFZ) 
study, done in mouse models to test the anti-TB activity, showed that a dose of 20 mg/kg 
daily yielded 0.55 µg/ml plasma concentration, and higher concentrations in the lung and 
liver (81, 82). This concentration of CFZ is bactericidal, but the onset of the drug is so slow 
that it may not stop death if the animal is heavily infected (81, 83). This type of screening 
therefore provides vital information of responses in a more complicated system. 
 
Figure 2.6: Physiological screening. Infected tissue (green) is treated with different candidate drug 
compounds to find potential hits. If the tissue is still infected (green) following the treatment the 
compound is discarded from the process. If the tissue is disease free (red) the compound is classified 
as a hit. 
 
Following the discovery of a number of hits, the drug discovery team must prioritize hits. 
Firstly, compounds that frequently show up during HTS as false positives are removed and 
secondly, hits are grouped according to structural similarity by computer algorithms (56). 
This is followed by measuring dose-response curves, i.e. the response at different dosages, 
using a fresh sample of the compound. Compounds that have reversible effects would be 
chosen above compounds that have an all or nothing response, since this would enable the 
drug to be removed from the patients system after withdrawal of the drug. 
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Secondary assays are also performed to exclude false positives that were identified during the 
primary assays (84). The methods used for secondary assays are not the high throughput 
methods, but focus more on the functional responses the compounds have (56).  
2.2.1.4. Hit Series Determination 
Hits are grouped into clusters that have structure-activity relationship (SAR) meaning these 
compounds have some related chemical motif or section of the overall structure. These 
groups enable testing to be done in parallel, generating SAR data and information of the 
elements for activity. Representative samples are selected from each group and subjected to 
an assortment of in vitro assays. These assays will provide information about the absorption, 
distribution, metabolism and excretion (ADME) properties together with pharmacokinetic 
and physicochemical measurements. Secondary tests can be carried out on these groups to 
profile the selectivity, especially the original target for which the compounds were made. 
The number of hits that move into the hit-to-lead phase should include all the compounds that 
showed activity to allow for the large loss of hits that occurs during the next phase. 
2.2.1.5. Hit-to-Lead 
The main aim of experiments done in this phase is to investigate the core of each structure 
and to measure the selectivity and activity of each compound (56). These investigations are 
done systematically to improve the SAR, and the availability of structural information 
improves this process.  
Optimization during the hit-to-lead phase depends on the technology used to screen for the hit 
discovery. The techniques used during the hit-to-lead process (Figure 2.7) may involve hit 
fragmentation, bioisosteric replacements or hit evolution or combinations of the techniques 
(85).  
Large molecules which have initially been identified by HTS mostly undergo hit 
fragmentation, which is when the HTS hits are structurally broken down to identify likely 
minimum ligands or fragments (86–88). New starting points which can be used for fragment 
expansion can be found by identifying the core fragments of HTS hits that have significant 
molecular complexity. This strategy has been used successfully to identify metalloenzyme 
inhibitors in a library screen of chelator fragments. 
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Figure 2.7: A diagrammatic representation of the hit-to-lead approaches explained in this 
review. During hit fragmentation an original drug-like hit is fragmented to undergo fragment 
based techniques. Bioisosteric replacement involves replacing a small part of the original drug-
like hit to obtain an optimized hit. During hit evolution fragments are added to the original 
drug-like hit to result in an optimized hit. (Adapted from (85)) 
 
Bioisosteric rules are used during the hit evolution technique of bioisosteric replacements. 
The term refers to two compounds that have a similar shape in a certain biological 
environment, for example a protein binding site (89). The method of bioisosteric 
replacements uses this biological similarity where the structure of the target is used to 
determine the similarity. However, the structure of the target is often not known, restricting 
the use of this method. In the course of PA-824 synthesis, the drug was insoluble because of a 
biaryl carbamate moiety, but by replacing the group with an arylpiperazine it resulted in PA-
824 being more soluble (90). 
During hit evolution, analogues with altered substitution patterns are chemically synthesised 
from the original hits. To create focused libraries (compound collections) the compounds are 
synthesised by solution- or solid-phase parallel synthesis, together with high throughput 
purification to aid the output of compounds for screening. Purified or crude compound 
analogues that have improved dissociation constants are screened using competitive 
conditions together with affinity screening methods (91). The SAR data gathered from these 
libraries can be used for medicinal chemistry exploration, in the hope to produce more 
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compounds which may have an enhanced lead-like profile, with physiochemical and 
structural profile of a good lead compound (85). 
When hit-to-lead optimization is successful, the drug-like lead compound that results from 
HTS hits does not depend on the original hit’s lead-likeness. According to Keserü & Makara 
(2006), “chemical similarity between hits and leads derived from them is somewhat larger for 
HTS hits (average 0.61) than that for fragment-based hits (average 0.56)” (85) The increase 
in ligand efficiency, i.e. the binding free energy for each heavy atom, of HTS hits during lead 
optimization is a clear indicator of the value this technique has (85, 92).  
Other important factors to consider are permeability and solubility of a drug, since the 
substance needs to be absorbed in the gastrointestinal tract or may be injected into the 
circulatory system (56). Unfortunately the amount of drug candidates that have low-solubility 
has increased, which is a significant problem for pharmaceutical companies performing drug 
design and development (93). 
2.2.1.6. Lead Optimization 
The main objective of lead optimization is to improve on the deficiencies of a compound 
whilst sustaining the favourable properties (56). Upon reaching this phase, the compound 
may have met all the requirements for lead optimization and can therefore be declared a 
candidate for preclinical trials. However, synthetic back up molecules need to be created, in 
case the compound that is undergoing preclinical or clinical characterization is unsuccessful, 
the back-up candidate can then be evaluated. 
Mutagenic qualities of a compound are assayed in the Ames test (94), while the Irwin’s test 
estimates the minimum concentration of a compound that is necessary for it to be lethal (95). 
Other tests that need to be carried out by the end of this phase are pharmacological studies to 
determine dose linearity, kinetics and pharmacodynamic properties. The effect of lead 
molecules on host metabolic processes also needs to be assessed.  
Only after all these hurdles have been overcome, the drug can be considered for human 
clinical trials. The whole process from target identification up to the selection of the 
preclinical candidate is a lengthy procedure and has no set routine; there are many different 
routes within this process that can be followed to reach the final preclinical candidate. Each 
project may start off with 2000 – 5000 compounds and through the preclinical phases only 
one or two molecules arise as candidates that will enter clinical trials (56).  
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2.2.2. Clinical Drug Trials 
New generation anti-TB drugs must undergo human clinical trials before they can be used in 
the general population. Clinical drug trials are divided into four phases. During phase I 
ADME properties of the drug are determined (96, 97). Drugs need to have a high penetration 
of bacterial cell envelopes, as efficiency is influenced by the amount of drug entering the cell 
(98).  
Initially 3-4 human participants are used to determine side effects of a specific single dose 
and if no adverse side effects occur the number of patients are increased up to 10 or 20 and 
the effect of multiple doses studied (97). In the case of the combination of drugs with no side 
effects, such as the combination of meropenem and clavulanate, the drug could proceed to the 
next phase (99). In some cases the side effects are manageable; such is the case with CFZ 
which causes a red-brown skin discolouration, but disappears after drug use is discontinued 
(100, 101). 
Phase II can be divided into two parts. In phase IIA, the dosing studies are done with 30 – 50 
participants to determine the optimal dose. Phase IIB comprises efficacy studies which are 
done to determine efficacy with a larger group of volunteers (200–500) (96, 97). This phase 
can last as long as up to 2 years to determine if the drug is efficient enough and if there are no 
long term side effects before going into phase III (97). 
Many more volunteers are needed for phase III studies to determine whether the efficacy of 
the drug shows statistical significance. More than a 1000 volunteers are used to assess if the 
drug is superior or equivalent to the current drugs but with fewer side-effects (96, 97). This 
phase is carried out in a clinical hospitals where the previous phases are normally in 
university or research based hospitals (97). During phase IV, no new tests done on the 
volunteers, but the previous volunteers are merely monitored to detect an adverse effects that 
may occur with prolonged use (97, 102). 
2.2.2.1. Drugs Currently in Clinical Trials 
Currently there are multiple drugs in various phases of the clinical trials. According to the 
Working Group on New TB Drugs (2014) there are currently no drugs in phase I, while there 
are several drugs in phase II, including PA-824, Linezolid, SQ-109, AZD5847 and Sutezolid. 
Among the drugs undergoing phase III trials are gatifloxacin, moxifloxacin, rifapentine and 
delamanid (OPC-67683). Most of these new drugs have the potential to be used against drug-
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resistant bacteria and to shorten treatment time (103). Table 2.3 displays the targets of these 
drugs however, not all of the targets have been determined. 
 
Table 2.3: Targets of drugs currently in clinical trials for TB therapy 
Drug Phase (104) Target 
AZD5847 IIA 50S Ribosomal Unit 
Bedaquiline IIB c Subunit of ATP Synthase 
PA-824,  IIA Mycolic Acid Biosynthesis 
Linezolid, PNU-100480 IIA 50S Ribosomal Unit 
SQ-109 IIA Arabinogalactan 
Sutezolid IIA 50S Ribosomal Unit 
Gatifloxacin, Moxifloxacin III DNA gyrase 
Rifapentine III RNA polymerase 
Delamanid (OPC 67683) III  Mycolic Acid Biosynthesis  
Adapted from (105) 
 
The Global Alliance of TB Drug Development (TB Alliance) currently has ongoing trials that 
test the efficacy of different drug regimens (106). CFZ is included in three of the arms of the 
New Combination 3 (NC003) trial, which is currently in phase IIA (106). The three 
combinations of drugs include BDQ + CFZ + PA-824 (JCPa), BDQ + CFZ + PZA (JCZ) and 
BDQ + CFZ + PZA + PA-824 (JCZPa). According to the TB Alliance the regimens are fixed 
dosages, orally administered, less expensive, can be used with antiretrovirals and show 
promise in shortening TB treatment to less than four months. However, there are already 
reports of drug resistance in patients using BDQ. To make matters worse, recent studies have 
identified cross-resistance between BDQ and CFZ caused by various mutations in Rv0678 
(107–109). The mechanisms of cross-resistance require urgent elucidation, as it has 
implications for patients with already limited therapeutic options. The development of 
resistance so soon after introduction into the clinical situation needs urgent attention, 
particularly in the area of resistance mechanisms and the development of proper diagnostics 
to identify such resistance. The previously reported change in minimum inhibitory 
concentration (MIC) was 2 fold (107), which may impede the effectivity of CFZ enough to 
render it inadequate for successful treatment. The outcome of these studies might result in 
BDQ and CFZ not being used together in a regimen as in the trials mentioned above.  
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Figure 2.8: New drug development pipeline for anti-TB drugs. HRZE is the standard drug regimen 
consisting of isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E). 
 
A new model has been designed for novel anti-TB drug development, as shown in Figure 2.8, 
where new promising drugs are tested in combination to shorten the amount of time from hit 
discovery to approval (110). Phase I trials, which include single ascending dose, multiple 
ascending dose, drug-drug interaction and ADME assessments, are conducted at the same 
time as preclinical in vitro and in vivo evaluations. This is done to determine the optimum 
candidate drug combinations aimed at shorter therapy time and prevention of relapse. The 
two parallel trials are followed by an early phase II trial (single drug) where the early 
bacterial activity (EBA) is determined over 14 days (110). EBA enables rapid detection of the 
effect a new drug may have using a limited amount of patients, selection of appropriate 
dosage for further trial experiments and studying of the relationship between bactericidal 
activity, toxicity of the drug and its pharmacokinetics (111). The use of EBA and 
pharmacokinetic studies give insight into drug behaviour in humans, such as appropriate 
dosages (112, 113). Based on the trials completed, a candidate drug regimen is developed and 
goes on to phase II EBA testing (combo EBA). Results of the phase II EBA testing are 
compared to the existing regimen of INH, RIF, PZA and EMB; if it was more successful, the 
regimen progresses to phase IIB where it is tested in drug susceptible and drug resistant TB 
patients for two months. If the data supports the efficiency of the new regimen, it is brought 
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into phase III where the safety and efficacy is tested. Currently the TB Alliance is using this 
model to develop a novel drug combination, to be used against drug sensitive M. tuberculosis 
and MDR-TB, which consists of PZA, MOX and PA-824 (114). A 14-day EBA study of the 
regimen has been completed, using a the standard regimen of INH, RIF, PZA and ETH as a 
control (114). This regimen has been advanced to phase IIA. 
2.3.  Conclusion 
The aim of discovering new drugs is to find a drug that shortens anti-TB treatment and has a 
defined mechanism of action which will combat acquisition of drug resistance. Before a new 
drug compound is allowed for large scale clinical use it has to undergo the rigorous tests to 
ensure the safety of patients. These tests take years, and most candidates do not make it to the 
market, which is one of the most important reasons why there have been so few new drugs in 
the last three decades. 
In December of 2012, for the first time in 40 years, an anti-TB drug, BDQ, was approved for 
clinical use against MDR-TB (115). BDQ has a novel mechanism of action against M. 
tuberculosis, namely the inhibition of the ATP synthase (116, 117). It is expected that in 
future, targeting of novel mechanisms of action, particularly those targeting metabolic 
pathways, will be able to curb the increase of MDR-TB prevalence.  
In summary, multiple new or repurposed drugs are currently in clinical trials and will 
hopefully reach the market in the near future to counter the widespread TB disease.  
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Chapter 3 
Material and Methods 
3.1. Clofazimine in vitro Mono-Resistant Mutant Generation 
A clinical pan-susceptible Mycobacterium tuberculosis progenitor, K636, was obtained from 
a culture bank maintained at the Department of Biomedical Sciences, Stellenbosch 
University. It was grown at 37
o
C for seven days in Middlebrook 7H9 broth (enriched with 
10% Albumin Dextrose Catalase (ADC), 0.5% Tween and 0.2% glycerol (7H9+ADC)). One-
hundred microliter aliquots were then spread plated, in quintuplicate, on Middlebrook 7H10 
agar (Becton, Dickinson and Co., Sparks MD, USA) (containing OADC (Oleic Albumin 
Dextrose Catalase; Becton, Dickinson and Co., Sparks MD, USA) and 2% glycerol), 
(7H10+OADC), and either 2.6 µg/ml (10× CFZ minimum inhibitory concentration (MIC)) or 
2.9 µg/ml of clofazimine (CFZ; Sigma-Aldrich, St. Louis, MO, USA) respectively. CFZ 
stock solutions were prepared in dimethyl sulfoxide (DMSO; 99%; Merck, New Jersey, 
USA) at a concentration of 500 µg/ml. To establish viability in the absence of the drug, serial 
dilutions from the culture were also plated on Middlebrook 7H10+OADC agar without CFZ. 
Plates were incubated for 30-40 days at 37
o
C before being inspected for the presence of M. 
tuberculosis colonies.  
The colonies observed on the 7H10+OADC plates were cultured in 50 ml tissue culture 
flasks (Greiner Bio-one, Maybachstreet, Germany), containing 10 ml 7H9+ADC. To exclude 
colonies that were tolerant, i.e. ability to survive in the presence of drug due to adaptive 
behaviour and not true drug resistance due to mutations, cultures were sub-cultured twice in 
10 ml 7H9+OADC without drug. The second set of sub-cultures were standardised to an 
optical density of 0.2, as measured at 600nm (OD600) in a spectrophotometer (Novaspec II 
Spectrophotometer, Pharmacia Biotech, England, UK), and exposed to 2.6 µg/ml CFZ for 64 
days at 37
o
C to verify true resistance to CFZ.  
Colonies that grew on 7H10+OADC+CFZ agar, were picked and cultured in 7H9+OADC. 
These clones were stored for further analysis.   
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3.2.  Characterisation of the Clofazimine Mono-Drug Resistant Mutant  
3.2.1. Growth Characteristics of Clones 
Growth kinetics were established by monitoring the OD600 of cultures over time. Selected 
clones were inoculated into a 10 ml 7H9+ADC starter culture. When these cultures reached 
mid-log phase, they were used to inoculate 50 ml 7H9+OADC in a 250 ml tissue culture flask 
(Greiner Bio-one, Maybachstreet, Germany) at 37
o
C. The starting OD was approximately 
0.050 - 0.070, and ODs were measured over a period of 28 days. Growth curves were done in 
biological triplicate, with technical duplicates of each biological replicate, and the mean OD 
readings at each time point were plotted on a graph. 
3.2.2. Cell and Colony Morphology 
Colony morphology was determined by visual inspection to assess colony size, shape, and 
colour. Cell morphology was determined through Ziehl-Neelsen (ZN) acid-fast staining, and 
cell shape and colour inspected using light microscopy, using 100× magnification and oil 
immersion (Olympus CX31,Olympus, Shinjuku, Tokyo, Japan). 
3.2.3. Strain Verification Using Spoligotyping 
Spacer oligonucleotide typing (spoligotyping) was done as previously described (118), to 
confirm that the CFZ resistant clones were members of the same family as K636. To amplify 
the DNA for spoligotyping, each polymerase chain reaction (PCR) consisted of 12.5µl of 
KAPA Taq 2× Readymix (KAPA Biosystems, Massachusetts, USA), 6.5µl H2O, 2µl of 
biotinylated DRa, 2µl of DRb, and 2µl DNA. The concentration of the primer stocks used in 
the PCR reaction was 5 pmoles/µl for DRa (5’-biotin- GGTTTTGGGTCTGACGAC) and 
DRb (CCGAGAGGGGACGGAAAC). The thermal cycling profile was 3 minutes at 95ºC, 
then 30 cycles of 1 minute at 94ºC, 1 minute at 55ºC and 30 seconds at 72ºC, followed by 10 
minutes at 72ºC. 
Following the PCR, 20µl of the products were added to 160µl of 2× saline sodium phosphate-
EDTA (SSPE; 1× SSPE = 1mM EDTA, 10mM NaH2PO4 and 0.18M NaCl) which was 
supplemented with 0.1% sodium dodecyl sulphate (SDS; Merck Laboratories, Saarchem, 
Gauteng, SA). The diluted PCR product was denatured at 99ºC for 10 minutes, followed by 
cooling on ice. The nitrocellulose membrane (Ocimum Biosolutions Inc, Hyderabad, India) 
was washed at 60ºC for 5 minutes with 250ml 2× SSPE-0.1% SDS, placed in a Miniblotter 
45 (Immunetics, Boston, Massachusetts, USA) along with a foam cushion, and all extra fluid 
was aspirated from the channels. The channels were filled with the PCR products, one sample 
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per channel. Incubation was done at 60ºC for one hour to allow hybridisation of the PCR 
product to the membrane.  
After hybridisation, samples were removed from the miniblotter system by aspiration. The 
membrane was then removed from the miniblotter and washed twice for 10 minutes each, in 
250ml 2× SSPE supplemented with 0.5% SDS at 60ºC. Following the washes, the membrane 
was incubated at 42ºC for 10 minutes, in 40ml of 2× SSPE-0.5% SDS containing 12µl of 
streptavidin-peroxidase conjugate (500U/ml stock; Roche, Germany). The membrane was 
washed twice in 250ml 2× SSPE-0.5% SDS at 42ºC for 10 minutes, followed by rinsing 
twice with 250ml 2×SSPE at room temperature for 5 minutes. Thereafter the membrane was 
incubated for one minute in 20ml electrochemiluminescent (ECL) detection liquid (AEC-
Amersham Co., Sandton, South Africa), covered with a transparent plastic sheet and exposed 
to light sensitive X-ray film for two to 20 minutes. The resultant pattern displayed on the X-
ray was used to visually identify the strain family to which the clones belonged. 
3.2.4. Minimum Inhibitory Concentration Determination in Liquid Media 
Drug susceptibility testing (DST) was done using the BACTEC™ MGIT™ 960 system 
(Becton, Dickinson and Co. Sparks MD, USA). Firstly, liquid cultures were prepared, from 
glycerol stocks, in 7H9+ADC broth. BACTEC™ MGIT™ Barcoded 7 ml tubes were 
inoculated with 100 µl from these cultures, followed by the addition of 800 µl of OADC 
supplement. Growth in the mycobacterial growth indicator tubes (MGITs) was monitored 
with the aid of the EpiCenter™ Microbiology Data Management System (Becton, Dickinson 
and Co. Sparks MD, USA). When the starter culture was scored positive (i.e., 400 relative 
growth units), the tubes were incubated for three more days, whereafter 100 µl was 
inoculated into new MGIT tubes and the growth process repeated. The new tubes were 
prepared as illustrated in Figure 3.1, containing drug concentrations of 0, 0.25 µg/ml, 0.5 
µg/ml or 1.0 µg/ml. The drug concentrations used during the CFZ MIC determination 
experiment were calculated using the equations explained in the Addendum to reach the final 
concentrations of 0.25 µg/ml, 0.5 µg/ml and 1.0 µg/ml.  
The MGIT tubes were incubated in the MGIT system at 37
o
C until the growth control (i.e the 
1/100 diluted sample) scored positive. At this point the samples were inspected and scored as 
sensitive or resistant. Samples with growth units above 100 were scored as resistant, while 
those below 100 units were scored as sensitive to the particular drug concentrations.  
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Figure 3.1: A schematic representation displaying the method used during setup for MIC 
determination in the BACTEC™ MGIT™ 960 system. 
 
3.2.5. Minimum Inhibitory Concentration Determination Using Agar Dilution Method 
The MICs of the CFZ resistant isolates were also determined on 7H10+OADC plates 
containing varying concentrations of CFZ (0.5 µg/ml, 1.0 µg/ml, 2.0 µg/ml, 2.5 µg/ml and 
3.0 µg/ml). Three biological replicates were used, each with two technical replicates. Briefly, 
liquid cultures of the progenitor and CFZ resistant isolates were grown to an OD between 
0.5-0.7 before 100 µl aliquots were plated on 7H10+OADC+CFZ and incubated at 37ºC. 
Dilutions of 1×10
-6
 of the progenitor and CFZ resistant isolates was also plated on 
7H10+OADC to determine the colony forming units per millilitre at the time of plating. MIC 
was defined as the killing off of 99% of the bacteria. 
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3.3. Whole Genome Sequencing Analysis of Clofazimine Resistant Strains 
3.3.1. DNA Extraction 
Genomic DNA was extracted as previously described by Warren et al., 2006. For this 
purpose, M. tuberculosis K636 and CFZ resistant clones were inoculated into 7H9+ADC 
broth from frozen stocks, and incubated at 37ºC for 14 days. Sub-cultures from these starter 
cultures were used to inoculate 7H10+OADC agar in 145x20mm Petri dishes. Plates were 
incubated at 37ºC for 20 days in order to obtain a lawn of growth on plates. Thereafter the 
plates were incubated at 80ºC for 30 minutes to heat-kill the M. tuberculosis cultures.  
To extract the DNA the heat-killed M. tuberculosis cultures were scraped with a sterile  
inoculating loop into a 50 ml Falcon tube containing 6ml extraction buffer (25 mM EDTA, 
5% sodium glutamate and 50mM Tris-HCl [pH 7.4]) and 20× 4mm glass beads. Duplicate 
cultures were pooled together in one tube.  
Tubes were vortexed for 2 minutes, to obtain a homogenous mixture, whereafter 500µl 
lysozyme (100 mg/ml, Roche, Germany) was added to break down the bacterial cell wall. 
RNA was digested with the addition of 2.5 µl heat treated RNAse A (10 mg/ml, Roche, 
Germany). The contents of each 50 ml tube were mixed by gentle inversion, followed by 
incubation for 2 hours at 37ºC. Thereafter the cells were lysed with the addition of 600µl of 
10× proteinase K buffer (50mM EDTA, 5% sodium dodecyl sulphate and 100mM Tris-HCl 
[pH 7.8]) and 300µl of Proteinase K (10 mg/ml, Roche, Germany). Tubes were mixed by 
gentle inversion and incubated for 16 hours at 45ºC.  
Subsequently protein and cell debris were removed by extraction with 5ml of 
phenol/chloroform/isoamyl alcohol (25:24:1). Briefly, the phenol/chloroform/isoamyl alcohol 
mixture was added to the proteinase K treated suspension and mixed by gentle and repeated 
inversion over a period of 2 hours. The aqueous and organic phases were separated by 
centrifugation (Eppendorf Centrifuge 5810R) at 3000 × g for 20 minutes at room temperature 
(25ºC). The aqueous top phase (containing the DNA) was transferred to a 50ml tube 
containing 5ml chloroform/isoamyl alcohol (24:1), mixed and centrifuged at 3000 × g for 20 
minutes at room temperature. Finally, the resultant aqueous phase was transferred to a new 
50ml tube which contained 600µl of 3M sodium acetate [pH 5.2] and the DNA was 
precipitated with the addition of an equal volume of cold isopropanol. Precipitated DNA was 
immediately collected using a glass rod and transferred to a new vial containing 1ml of 70% 
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ethanol. DNA was then air dried whereafter it was dissolved in 300µl of Tris-EDTA (TE) 
buffer (1mM EDTA, 10mM Tris-HCl [pH8.0] and stored at -20 º C until further use. 
3.3.2. Whole Genome Sequencing 
3.3.2.1. MiSeq Illumina Sequencing 
DNA from the progenitor (K636) (n=1) and CFZ resistant clones (n=2) were sequenced using 
the Illumina MiSeq platform with the MiSeq Reagent Kit v3 at the Institute for Microbial 
Biotechnology and Metagenomics at the University of the Western Cape, South Africa. The 
MiSeq Kit v3 allows 600 cycles, leading to longer read lengths. 
3.3.2.2. Computational Analysis of Whole Genome Sequencing Data 
 
 
Figure 3.2: The WGS pipeline followed during bioinformatic analyses of the Illumina MiSeq 
sequencing data. 
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The MiSeq Illumina sequencing data was analysed in collaboration with Dr RG van der 
Merwe (Stellenbosch University, RSA) and Dr M de Vos (Stellenbosch University, RSA). 
An overview of the bioinformatic analysis pipeline that was used is shown in Figure 3.2. 
3.3.2.3. Data Source 
The genome summary information and genome sequences (in FASTA format) of the 
reference genome (M. tuberculosis H37Rv) were downloaded from GenBank (accession 
number: AL123456.3) (119). 
3.3.2.4. Quality Control and Alignment 
Quality Assessment 
The quality of the raw sequence reads was validated using Babraham Bioinformatics FastQC 
software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). This is java-based 
software that outputs HTML files from fastq input files.  
Trimming Reads 
Trimmomatic v0.32 (120) was used to trim the adaptor and low-quality bases (Quality 
threshold of 33) from the raw sequence reads. The Phred score used was 33, which allows a 
0.0005% chance of error. Error probability in calling bases is logarithmically related to the 
Phred quality score (Q), for example when Q = 7log10, there is a 1 in 7 chance of error.  
The “ILLUMINACLIP” function of Trimmomatic was used with 2 as the maximum amount 
of mismatches allowed, 30 as the accuracy needed between two reads for palindrome paired-
end read alignment and 10 to specify the accuracy needed between any adapter sequence and 
read to allow it to match.  
To trim the bases of low quality from the beginning and end of the read the “LEADING” and 
“TRAILING” functions were used respectively, keeping any base at the ends of the read with 
a quality higher than 15. 
Through the consideration of multiple bases, referred to as a window, the 
“SLIDINGWINDOW” function prevents the removal of high quality data in a window 
containing a single base of poor quality. The quality of a base is determined by the Phred 
score. The amount of bases included in the window, to average across, was set to 4 and the 
average required quality was set to 20. Reads that are below a minimal length of 15 were 
removed using the “MINLEN” function. 
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Alignment of Reads 
Alignments of raw sequence reads were done against the M. tuberculosis H37Rv reference 
genome using three aligners, Novoalign v3-02-04 
(http://www.novocraft.com/main/index.php), Burrows-Wheeler Alignment tool (BWA) 
v0.7.8 (121) and SMALT v0.7.5 (https://www.sanger.ac.uk/resources/software/smalt/#t_1) . 
The use of three aligners, which apply different algorithms, minimizes the amount of false 
positives, i.e. bases which are misaligned by a single algorithm. These three aligners produce 
SAM files which are required to continue through the pipeline. 
Novoalign 
Novoalign aligns reads generated during Illumina WGS using the Needleman-Wunsch 
algorithm with gap alignment. The reference genome was indexed using the “novoindex” 
command with 13 and 1 as the k-mer indexing size and indexing step size respectively.  
Burrows-Wheeler Alignment tool (BWA) 
BWA aligns short reads to a reference genome (121), in this case M. tuberculosis H37Rv. 
BWA uses Burrows-Wheeler Transform (BWT) with backward search. This tool mimics the 
digital tree top-down traversal of the genome, using a relatively small amount of memory, 
counting the exact number of hits a string of a certain length has in a certain time, irrespective 
of the genome size.  
The reference genome was also indexed using the “faidx” function from SAMtools 
(http://samtools.sourceforge.net). The BWA “aln” command was used to find coordinates of 
good hits for suffix array (SA) in every read, followed by the “sampe” command which 
produces a SAM file by converting the SA coordinates into chromosomal coordinates.  
SMALT 
The reference genome was indexed using the “index” command from SMALT. Subsequently 
this software uses a banded Smith-Waterman algorithm where the sequence segments from 
the reference genome are matched to the indexed reads. A reliability score for the mapping of 
each read is reported along with its best gapped alignments. 
SAM file validation 
To validate the SAM file, produced during alignment, the Picard v1.107 
(http://picard.sourceforge.net) “ValidateSamFile” command was used. 
Stellenbosch University  https://scholar.sun.ac.za
 31 
 
3.3.2.5. Post Alignment Processing 
Conversion of SAM to BAM 
Using the “view” command from SAMtools, a SAM file post processor, the SAM files were 
converted to the binary (BAM) format. 
Sorting and Indexing of BAM files 
To convert the BAM file to a more manageable format the “sort” and “index” SAMtools 
functions were used. 
Local Realignment Around Insertions and Deletions 
The Genome Analysis Toolkit (GATK) v3.1-1 (122) was used to realign misaligned reads by 
insertions and deletions (InDels) within the sequenced genome. Firstly the SAMtools “faidx” 
command was used to create a FASTA index file for the reference genome. Subsequently a 
dictionary file was also made using the “CreateSequenceDictionary” command from Picard. 
To fix misaligned reads, small misaligned intervals are identified using the Realigner Target 
Creator tool, followed by realignment of identified intervals to the reference genome, using 
the IndelRealigner tool from GATK. 
Realigned BAM files Sorting and Indexing 
The “sortsam” function from Picard, and “index” function from SAMtools was used to sort 
and index the realigned BAM files respectively. 
PCR Duplicate Removal 
During PCR amplification for library construction the production of duplicate reads may 
occur. To find and remove these duplicates in the BAM file, the “Mark Duplicates” Picard 
command was used. 
Indexing Realigned BAM file 
The realigned BAM file, where the PCR duplicates have been removed, was indexed using 
the “index” function from SAMtools. 
3.3.2.6. Variant Calling 
To identify variants, i.e. single nucleotide polymorphisms (SNPs) and InDels in the 
sequenced genomes, H37Rv was used as a reference. Variants were called using the GATK 
UnifiedGenotyper tool which produced a Variant call format (vcf) file. The “stand_call_conf” 
command was used to set the minimum Q confidence to 50, which will allow the variant 
caller to call variants with a minimum Q value of 50. The “stnd_emit_conf” command was 
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set to 10, which will allow the variant caller to include variants with a Q value of less than 50 
but more than 10. The information pertaining to a variant base which includes the number of 
reads at that position along with the number of reads which contained the alternative and 
reference base at the specific position. 
3.3.2.7. Extracting Overlapping SNPs from Various Pipelines 
The combination of three aligners (Novoalign, BWA and SMALT), with GATK as a variant 
caller, minimizes the risk of identifying false positive variants as three different pipelines 
were used for SNP and InDel identification (Figure 3.3) namely Novoalign-GATK, BWA-
GATK and SMALT-GATK. Overlapping SNPs generated by the three pipelines were 
extracted using in-house python scripts (RG van der Merwe, unpublished data). For each 
aligner a vcf file was created containing the identified SNPs and InDels. Extraction of SNPs 
and InDels present in all three vcf files identified high confidence SNPs creating a final vcf 
file. Only variants that were identified in all three pipelines were considered during further 
analysis. 
 
Figure 3.3: A diagrammatic representation of the strategy followed to extract SNPs and InDels. 
The variants used for further analyses is represented by G, where the SNPs and InDels extracted by 
(A) Novoalign, (B) BWA and (C) SMALT overlap. The SNPs and InDels identified by only one (A, 
B or C) or two (D, E and F) aligner(s) are included in the final vcf file, but not investigated further. 
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3.3.2.8. SNPs/InDels Annotation and Functional Classification 
Python scripts were written by Dr RG van der Merwe for; i) annotation of identified SNPs, ii) 
calculation of predicted amino acid changes for SNPs located within genes, iii) annotation of 
the identified InDels, iv) calculation of InDel effects on the respective gene’s reading frame, 
and v) classification of the variants according to its cellular function. 
3.3.2.9. Validation 
GenomeView 
The SNPs and InDels that were identified in genomic DNA during variant calling were 
visualised in each individual read using the GenomeView browser (http://genomeview.org/) 
graphical user interface. The H37Rv indexed FASTA file was loaded as the reference 
genome along with the sorted and indexed BAM files from the sequenced genomes. 
GenomeView shows the aligned reads, hence the amount of reads containing the variant or 
alternative at a specific base can be visualised. 
Validation of Variants Using Sanger Sequencing of Target Regions  
Primer Design 
Primers were designed, using Primer3 (http://primer3.ut.ee/), to amplify regions containing 
the identified variants (Table 3.1). 
  
Table 3.1: Primers used for targeted Sanger sequencing. 
Target 
gene 
Primer Sequence Product Size 
(bp) 
Tm 
(ºC) 
Rv0678 Forward 
Reverse 
5’ AAAGCAGTAGGTCAGGGCAT 3’ 
5’ CTCGTTGTTGTTGGGCTGG 3’ 
1147 59 
Rv2941 
(fadD28) 
Forward 
Reverse 
5’ CATGAGTGTGCGTTCCCTTC 3’ 
5’ TAACCCGAACGTTCTGATGG 3’ 
572 61 
Rv3696c 
(glpK) 
Forward 
Reverse 
5’ CGCCGGCAACTTATTTCTCT 3’ 
5’ CACACCGTGGTTAGCAGG 3’ 
496 61 
 
Polymerase Chain Reaction (PCR) Conditions 
PCR reactions were carried out using the Thermal Cycler 2720 (Applied Biosystems, Foster 
City, CA, USA). Each reaction consisted of 9.375 µl of H2O, 5 µl 5× Q solution, 2.5 µl 10× 
µl buffer, 2 µl MgCl2, 4 µl dNTPs (25 mM), 0.5 µl of the forward primer (50 pmol/µl), 0.5 µl 
of the reverse primer (50 pmol/µl), 0.125 µl HotStarTaq DNA Polymerase (Qiagen, 
Düsseldorf, Germany) and 1 µl of template DNA. The cycling conditions used were as 
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follows: (i) denaturing for 15 minutes at 95ºC, (ii) 35 cycles of denaturing for 1 minute at 
94ºC, annealing for 1 minute at Tm, extension for 1 minute at 72ºC and (iii) final extension 
for 10 minutes at 72ºC. A negative control containing no DNA template was included in each 
experiment. 
Gel Electrophoresis 
PCR products were prepared adding 5 µl of blue loading dye (0.25% Xylene Cyanol, 30% 
Glycerol) to 25 µl of the amplification product. Five microliter of each amplification reaction 
was loaded onto a 1.5% agarose gel. To determine the size of the PCR product, the 
GeneRuler 100 bp Plus DNA Ladder (Thermo Scientific, Pittsburgh, PA, USA) was loaded 
into an adjacent well. The amplicons and DNA ladder were electrophoretically fractionated in 
1.5% agarose gel (containing 5 µl ethidium bromide (10 mg/ml) per 100ml agarose) and 1× 
Tris-Borate-EDTA (TBE; 0.45M Tris, 0.44M boric acid and 10mM EDTA; pH8.3) buffer for 
approximately 2-3 hours at 120 V, followed by visualization under ultra violet light using the 
Kodak Digital Science Electrophoresis Documentation and Analysis System 120 
(VilberLourmat, France). 
Sanger Sequencing 
PCR products were purified using the Wizard® SV Gel and PCR Clean-Up System 
(Promega, Madison, WI, USA). Sanger sequencing of PCR products were done at the Central 
Analytical Facility, Stellenbosch University. To determine the presence of polymorphisms in 
the gene region of interest, the CFZ resistant DNA sequences were aligned and compared to 
the M. tuberculosis K636 progenitor using BioEdit Sequence Alignment Editor (123).  
3.4. Virtual Protein Visualisation 
3.4.1. Protein Modelling 
Wild type Rv0678 and the mutated protein which was identified in CFZ resistant clones were 
compared using protein modelling. The crystal structure of the wild type protein (PDB 
structure: 4NB5) was obtained from the Protein Data Bank (accession number: I6Y8F7) 
(124). The SWISS-MODEL Workspace, a homology-modelling server was used to model the 
mutated Rv0678 protein, using 4NB5.1.D as a template (125–127). Following the selection of 
4NB5.1.D the “Target Prediction” was set to build a homo-tetramer. The model was 
predicted by SWISS-MODEL and a “pdb” file was obtained containing the predicted mutated 
Rv0678. 
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3.4.2. Visualisation Using Chimera 
Chimera v1.9 (128) was used to visualise 4NB5 and the virtually modelled protein containing 
the non-synonymous SNP identified during WGS. Analysis of the 3D structures was 
performed on 4NB5 and the mutated Rv0678 to elucidate the influence that the non-
synonymous SNP may have on the protein structure. 
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Chapter 4 
Results 
4.1. Clofazimine in vitro Mono-Resistant Mutant Generation 
Nine clofazimine (CFZ) resistant colonies were initially obtained following the exposure of 
the pan-susceptible progenitor, M. tuberculosis K636, to 2.6 µg/ml CFZ. No growth was 
observed following exposure to 2.9 µg/ml CFZ.  Subsequent sub-culturing in mycobacterial 
growth indicator tubes (MGIT) and re-exposure to CFZ showed that 5 of these isolates 
(CFZR2, CFZR6, CFZR7, CFZR8 and CFZR9) were resistant to the 0.5 µg/ml CFZ. These 5 
isolates were characterised further.  
4.2. Characterisation of the Clofazimine Mono-Drug Resistant Mutants 
4.2.1. Growth Characteristics of Clones 
The growth characteristics of CFZ resistant clones were identical to the susceptible 
progenitor K636 when cultured in 7H9+ADC at 37°C (Figure 4.1).  
 
Figure 4.1: Growth curve comparing the progenitor M. tuberculosis strain (K636) and CFZ 
resistant clones (CFZR2, CFZR6, CFZR7, CFZR8 and CFZR9).  The graph was plotted using the 
mean OD obtained from 3 biological, independent experiments. Error bars indicate the standard error 
around the mean of each value. 
 
4.2.2. Colony and Cell Morphology 
There was no difference in colony morphology observed between the progenitor M. 
tuberculosis strain (K636) and CFZ resistant clones. 
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Figure 4.2 shows the Ziehl-Neelsen (ZN) acid-fast staining of cells of K636 and the CFZ 
resistant clones CFZR2, CFZR6, CFZR7, CFZR8 and CFZR9. These microscopic views 
suggest that the cell morphology of the mutants was the same as the wild type strain, and that 
they were members of the genus Mycobacteria. 
 
Figure 4.2: Images displaying Ziehl-Neelsen acid fast staining. (A) Progenitor M. tuberculosis 
strain (K636), (B) CFZR2, (C) CFZR6, (D) CFZR7, (E) CFZR8 and (F) CFZR9. 
 
4.2.3. Strain Verification Using Spoligotyping 
The spoligotype of the progenitor, K636, was identical to that of the CFZ resistance clones 
CFZR2, CFZR6, CFZR7, CFZR8 and CFZR9 (Table 4.1). This confirms that the CFZ 
resistant colonies were from the same genotype (Beijing) as K636. 
Table 4.1: The spoligotyping results of the progenitor, K636, and the CFZ resistant mutants, 
CFZR2, CFZR6, CFZR7, CFZR8 and CFZR9. 
Isolate Spoligotype 
K636 
CFZR2 
CFZR6 
CFZR7 
CFZR8 
CFZR9 
A B C 
D E F 
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4.2.4. Minimum Inhibitory Concentration Determination in Liquid Media 
The minimum inhibitory concentration (MIC) of the progenitor (K636) was <0.25 µg/ml. In 
comparison the MICs for the CFZ resistant clones CFZR2, CFZR6, CFZR8 and CFZR9 were 
>0.25 µg/ml and <0.5 µg/ml, while the MIC for CFZR7 was >0.50 µg/ml (Table 4.2). 
Table 4.2: Minimum inhibitory concentration (MIC) of the progenitor (K636) and the CFZ 
resistant isolates (CFZR2, CFZR6, CFZR7, CFZR8 and CFZR9). 
Isolate CFZ MIC 
K636 <0.25 µg/ml 
CFZR2 >0.25 µg/ml 
CFZR6 >0.25 µg/ml 
CFZR7 >0.50 µg/ml 
CFZR8 >0.25 µg/ml 
CFZR9 >0.25 µg/ml 
 
4.2.5. Minimum Inhibitory Concentration Determination Using Agar Dilution Method 
Following exposure to 0.5 µg/ml CFZ the progenitor, K636, did not grow, while the CFZ 
resistant isolates grew in abundance. At a CFZ concentration of ≥1.0 µg/ml no growth was 
observed. 
Table 4.3: The optical densities at which the clones were plated and the colony forming units of 
the clones at CFZ concentrations 0 µg/ml, 0.5 µg/ml, 1.0 µg/ml, 2.0 µg/ml, 2.5 µg/ml and 3.0 
µg/ml. 
Isolate 
OD 
when 
plated 
CFUs/ml at 
0 µg/ml 
CFZ 
CFUs/ml at 
0.5 µg/ml 
CFZ 
CFUs/ml at 
1.0 µg/ml 
CFZ 
CFUs/ml at 
2.0 µg/ml 
CFZ 
CFUs/ml at 
2.5 µg/ml 
CFZ 
CFUs/ml at 
3.0 µg/ml 
CFZ 
K636 0.477 155×10
6 
0 0 0 0 0 
CFZR2 0.600 615×10
6
 >2500 0 0 0 0 
CFZR6 0.685 763×10
6
 >2500 0 0 0 0 
CFZR7 0.654 730×10
6
 >2500 0 0 0 0 
CFZR8 0.563 722×10
6
 >2500 0 0 0 0 
CFZR9 0.699 830×10
6
 >2500 0 0 0 0 
 
4.3. Whole Genome Sequencing 
Bioinformatic analyses using three alignment methods identified a total of 3 chromosomal 
variants uniquely present in all of the CFZ resistant clones described here (Table 4.4). 
Targeted sequencing validated the three identified variants. A g250a non-synonymous single 
nucleotide polymorphism (SNP) was identified in Rv0678, causing an amino acid (AA) 
change from Alanine to Threonine at codon 84.  
A second mutation was observed in the Rv2941 gene, where a 92 bp deletion was found 
which led to a premature stop codon. This premature stop resulted in the production of a 
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potential truncated protein of only 71 AA compared to the 580 AA encoded by the wild type 
gene.  
The third mutation was the result of a 1 bp insertion in gene Rv3696c, resulting in the 
truncation of the GlpK glycerol kinase protein from 517 AA to 70 AA because of a premature 
stop codon. 
Table 4.4: The variants identified during WGS of K636 and CFZR2 and CFZR7. 
Gene Protein SNP/Insertion/Deletion 
Effect on protein or 
gene 
Rv0678 Regulator g250a 
Changed AA 
(A84T) 
Rv2941 
Fatty-acid-AMP-Ligase 
(FadD28) 
92 bp deletion at 161 
Premature stop 
codon in gene 
(Q71STOP) 
Rv3696c Glycerol Kinase (GlpK) 1 bp insertion at 573 
Premature stop 
codon in gene 
(E252STOP) 
 
4.4. Virtual Protein Visualisation 
The mutation at codon 84 in Rv0678 results in the replacement of the non-polar amino acid 
alanine with a polar amino acid, threonine, in the CFZ resistant clones (Figure 4.3). 
Threonine has two extra side chains which may influence the binding of the regulator, 
Rv0678, to DNA. Chimera v1.9 was used to visualise protein 4NB5 (124), representing the 
crystal structure of Rv0678, as well as the virtually modelled Rv0678 mutated protein (125–
127). This enabled us to determine the effect of changed amino acids on the protein and how 
this change potentially could influence its interaction with its target.  
 
Figure 4.3: The (A) alanine, in the wild type, and (B) threonine, in the mutant, found at amino 
acid 84 in Rv0678. 
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Figure 4.4: The surface of wild type Rv0678, showing DNA binding domains in purple (amino 
acid 82), yellow (amino acid 90) and red (amino acid 88), and amino acid 84 in dark blue.  
 
Figure 4.5: The codon 84 Rv0678 mutant, where the DNA binding domains are coloured coral 
(amino acid 82), blue (amino acid 88) and orange (amino acid 90), while amino acid 84 is 
coloured yellow.  
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Figure 4.6: The surface of wild type Rv0678 showing the hydrophobicity of the protein, and all 
four of the amino acids at 84 in the homotetramer are circled.  
 
Figure 4.7: The surface of the mutated Rv0678, showing the hydrophobicity of the proteins, and 
all four of the 84th amino acids in the homotetramer are circled.  
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The A84T mutation at amino acid 84 is in the region of the DNA binding domain, which can 
be seen in Figure 4.4 and Figure 4.5. In Figure 4.6 and Figure 4.7 the change from 
hydrophobic to neutral caused by the mutation at amino acid 84 is displayed. 
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Chapter 5 
Discussion 
5.1. Mutations Identified in Clofazimine Resistant Isolates 
During this study, a number of spontaneous clofazimine (CFZ) resistant mutants, with a 2 
fold increase in minimum inhibitory concentration (MIC), were isolated from a clinical M. 
tuberculosis isolate following culture on media containing CFZ.  These clones were all 
characterised by the same chromosomal mutations, namely a non-synonymous single 
nucleotide polymorphism (SNP) in Rv0678, a deletion in Rv2941 and a single base-pair 
insertion in Rv3696c. Although mutations in Rv0678 had been described previously, both in 
in vitro generated and clinical CFZ-resistant isolates (107, 108), all the mutations described 
in this study were novel and had not been previously described in the literature. These 
mutations occurred in genes involved in either the uptake or generation of specific nutrient 
components needed by M. tuberculosis. However, we could find no evidence to suggest that 
these mutations influenced the in vitro growth rate of the CFZ resistant mutants when 
compared to the wild type progenitor. This may be explained by the fact that the mutant 
clones were cultured on enriched media (7H9+ADC). Furthermore, there were no differences 
in the colony morphology of the progenitor and CFZ resistant mutant clones. This was 
expected since none of the genes with identified mutations has been reported to play a role in 
cell formation and division. 
5.1.1. Rv0678 
Although the mutation described in Rv0678 was novel, earlier studies had identified 
mutations in Rv0678, a MarR-like regulator, in CFZ resistant isolates (107, 108). These 
studies observed that the S63R, S68G, R134STOP mutations, as well as frameshift mutations 
(caused by insertions at basepair 38 and 192) caused in vitro resistance to CFZ (107, 108). 
Sequencing of in vivo CFZ resistant isolates from patients also identified additional mutations 
W42R, T33A, A36V and frameshift mutations (caused by insertions at basepair 141 and 172 
and a deletion at basepair 212)  in Rv0678 (107).  
Not much is known about the role of the MarR-like regulator in M. tuberculosis. However, 
MarR regulators from other bacteria are known to control several important biological 
processes, including the production of virulence factors, oxidative stress responses and 
antimicrobial resistance (129). A search of the available literature revealed that mutations in 
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the M. tuberculosis MarR-like transcriptional regulator, encoded by Rv0678, were previously 
indicated in azole resistance in M. tuberculosis (130).  
Mutations in Rv0678 appeared to be linked to increased expression of an efflux pump which 
are encoded by genes situated directly upstream of Rv0678 (108). Although we did not 
evaluate the expression of these genes in this study, it is plausible that the same phenomenon 
could be true for the CFZ resistant mutants described here. This suggests that the A84T 
mutation in Rv0678, identified in this study, causes upregulation of MmpS5-MmpL5 
(mycobacterial membrane protein small 5 – mycobacterial membrane protein large 5), which 
is proposed to play a role in siderophore transport (131). A recent study found that the 
overexpression of MmpS5-MmpL5 leads to 2× increase in CFZ resistance (107) which 
corresponds to our observation that the CFZ MICs were increased by 2 fold. Rv0678, the 
MarR-like regulator contains a DNA binding domain targeting the DNA upstream of these 
genes. This binding interaction was confirmed using mobility gel-shift assays using DNA 
fragments complementary to the promoters of mmpL5, mmpL2 and mmpL4 operons (124). 
The gene encoding the regulator is also situated immediately downstream from this mmpS5-
mmpL5 operon in M. tuberculosis (Figure 5.1) (124).  
 
Figure 5.1: The regulator gene, Rv0678, is located downstream of the mmpS5-mmpL5 operon. 
 
Rv0678 encodes a protein of 165 amino acids which forms a homodimer which in turn 
combines to form an asymmetric unit, consisting of two homodimers (124). According to 
Radhakrishnan et al. (2014) “three residues, Arg-84, Asp-90, and Arg-92, are located within 
the DNA-binding domain of the regulator and are probably important for protein DNA 
interactions” (124). Upon purification of the protein encoded by Rv0678, the fatty acid 2-
stearoylglycerol was co-purified with the protein (124). Ligand screening indicated that this 
fatty acid molecule is buried completely within the interface of the dimer (124). This suggests 
that this fatty acid potentially plays a regulatory role in the mechanism of Rv0678. MarR type 
regulators have multiple substrates depending on the process being regulated (132), in one 
instance uric acid was found to bind to the MarR type regulator and thereby antagonize 
DNA-binding (133). 
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The mechanisms whereby MmpL proteins affect M. tuberculosis phenotypes are currently 
under investigation (134, 135). There are 13 MmpL proteins, in the M. tuberculosis genome, 
which are involved in efflux of multiple substrates. These MmpL proteins form part of the 
RND proteins which are involved in nodulation, cell division and resistance to antibiotics 
(135). MmpL proteins work together with MmpS as an efflux system. Evidence shows that 
these efflux systems are involved in lipid and fatty acid export (131, 135–139). 
 
Figure 5.2: A schematic representation of the M. tuberculosis siderophore-mediated uptake of 
iron. Cytoplasmic synthases synthesise siderophores, which are suspected to be transported by the 
MmpS4-MmpL4 and MmpS5-MmpL5 export systems. The MmpS4 and MmpS5 proteins are situated 
in the plasma membrane, and coupled with their MmpL4 and MmpL5 counterparts respectively. A yet 
undiscovered cell wall protein would be required to export siderophores over the cell wall. Outside 
the cell siderophores bind to iron and requires another undiscovered cell wall protein to transport the 
complex back across the cell wall. IrtAB imports the ferric-siderophore from the periplasmic across 
the plasma membrane into the cytoplasm. Here the iron is available to the cell after releasing from the 
siderophore. (Adapted from (131))  
 
It has been suggested that MmmS5-MmpL5 exports the siderophores; mycobactin and 
carboxymycobactin (131) (Figure 5.2). Siderophores bind to ferric iron (Fe
3+
) outside the 
cell, transports it across the cell membrane and releases ferrous iron (Fe
2+
) inside the cell 
(Figure 5.2). Fe
2+
 acts as an electron donor or acceptor in the electron transport chain (140). 
The electron transport chain drives adenosine triphosphate (ATP) synthesis, an essential 
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pathway for survival of the bacterium. It is thus plausible that upregulation of MmpS5-
MmpL5 may lead to a higher level of iron within the cell. This could influence the levels of 
menaquinone in the cell, as it has been found that growing M. tuberculosis in an iron rich 
environment leads to a higher level of menaquinone than when grown in an iron-limited 
environment (141). 
CFZ competes with menaquinone to be reduced by quinone oxidoreductase, a mycobacterial 
type II NADH oxidoreductase (NDH-2) (12). This NDH-2 has an essential role in the growth 
of M. tuberculosis because of this menaquinone reduction function. Other menaquinone 
producing resources within M. tuberculosis include mycobacterial type I NADH 
oxidoreductase (NDH-1) and succinate oxidoreductase (142). 
Iron is an essential component for NDH-1 synthesis within the cell, since NDH-1 possess 
iron-sulphur cluster subunits (143). This suggests that the increase of iron within the cell, 
caused by the upregulation of MmpS5-MmpL5, could increase the amount of NDH-1 
synthesised. An increase in the amount of NDH-1 present in the cell could lead to an increase 
in menaquinone reduction, counteracting the influence of CFZ. 
Another explanation for increased CFZ resistance, caused by the upregulation of the MmpS5-
MmpL5 efflux pump, could be the increase in efflux of the drug itself. Isoniazid resistance 
has been conferred through the overexpression of M. tuberculosis MmpL7 in M. smegmatis 
(144). Through the use of efflux pump inhibitors the MIC was decreased, confirming the 
influence of the efflux pump on isoniazid resistance (144). 
Our observed lack of an influence on growth of the CFZ resistant mutants could be explained 
by the presence of iron in the 7H9+ADC, which is freely available in large quantities to the 
wild type, K636, in vitro (145, 146). However, studies with iron depleted media, or in vivo 
studies may display different results, since iron is not freely available to the organism, which 
could influence the growth.  
5.1.2. Rv2941 
The CFZ resistant mutants described here also contained a deletion in the Rv2941 gene, 
which encodes a fatty-acid-AMP ligase (FadD28). The enzyme is involved in the production 
of the phthiocerol dimycocerosate (PDIM), a known M. tuberculosis virulence factor (147, 
148). The 92 bp deletion identified in the gene causes a significant truncation of the protein. 
Not much is known about PDIMs and M. tuberculosis drug resistance, but a recent paper 
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showed elevated PDIM production in rifampicin resistant M. tuberculosis isolates (149). 
Conversely, diminished PDIM activity was shown to increase M. tuberculosis sensitivity to 
drugs and detergents, indicating an impaired cell and perhaps more permeable envelope 
protection (150).  
Previous studies have not yet linked FadD28 to CFZ resistance. However, a recent study did 
find a mutation in ppsC in a CFZ resistant isolate with a mutation in Rv0678 (107). PpsC is 
involved in PDIM biosynthesis (150). There are three transcriptionally related units (Figure 
5.3); (i) the first stretches from fadD26 to papA5, (ii) the second consists of the mas gene, and 
(iii) the third include the open reading frame of fadD28 and mmpL7 (150). This suggests that 
the mutations in the genes responsible for PDIM synthesis may influence CFZ resistance. 
However, unfortunately no conclusions can be made about the role of FadD28 in CFZ 
resistance as no further studies have been done here to establish its role in these CFZ resistant 
clones. 
 
Figure 5.3: The transcriptional related units 1-3; unit 1 contains ppsC and unit 3 contains 
fadD28. (Adapted from (25)) 
 
The truncation of FadD28 did not influence the growth of the organism in vitro. This is in 
line with observations that in vitro growth of M. tuberculosis does not require PDIM 
virulence factors (151). Conversely other studies have found that when M. tuberculosis 
H37Rv loses PDIM synthesis (when grown in vitro for extended periods of time) this leads to 
attenuated growth in vivo (151, 152). 
5.1.3. Rv3696c 
The last gene that was found to be mutated in these CFZ resistant mutants was Rv3696c, 
encoding glycerol kinase (GlpK). This enzyme converts glycerol to glycerol-3-phosphate, 
which enters the central carbon metabolism (153). Glycerol-3-phosphate production in M. 
tuberculosis “is essential for membrane and fatty acid metabolism involving fatty-acyl 
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glycerol phosphates and interconversions between CDP-diacyl-glycerol and phosphatidyl-
glycerol phosphates” (154). However, it is not essential for growth in vivo in mice (61).  
The truncation of GlpK, in this study, is the result of a 1 bp insertion. Mutations in GlpK 
have not previously been linked with resistance to CFZ. This mutation also does not seem to 
influence in vitro growth. However, previous studies using either transposon site 
hybridisation or knockout mutants of GlpK showed a negative effect on growth on glucose 
enriched media (45, 155). The knockout mutant of GlpK failed to grow on glycerol minimal 
media (45). Another study where a M. bovis glpK mutant was generated the protein was 
truncated due to a frameshift. This mutant could not survive on glycerol media, pyruvate had 
to be added before growth was observed (156). GlpK is needed in vivo to metabolize 
glycerol, the carbon source for the organism within the host. Since glucose is present in 
7H9+ADC, GlpK may not be necessary for in vitro growth.  
5.2. Clinical Consequences of Clofazimine Resistance 
CFZ currently is one of the drugs reserved as a last resort in tuberculosis (TB) therapy. 
Current clinical trials are also looking at its interaction with newer available drugs, in an 
effort to find more effective therapies for drug resistant TB. In leprosy, where this drug is 
currently in use, drug resistance is rare (10). This may be explained by the absence of Rv0678 
and mmpS5-mmpL5 in M. leprae (157–163).  
Older literature suggested that CFZ does not induce resistance in M. tuberculosis, but recent 
studies clearly demonstrated the development of CFZ resistant both in vitro and in patients 
(83). Not only does exposure to CFZ result in resistance, but exposure to one of the new anti-
TB drugs also generates CFZ resistance. The observed cross-resistance between bedaquiline 
(BDQ) and CFZ may influence treatment regimens, particularly if alternative therapeutic 
options are not available. Such induced cross resistance was recently described in a Tibetan 
man admitted with multiple drug-resistant TB (MDR-TB) in January 2011 (109). The patient 
was initially treated with a combination of ethambutol (EMB), para-aminosalicylic acid 
(PAS), cycloserine (CYC) and capreomycin (CAP) (109). From September 2011 to February 
2012 the patient also received BDQ on compassionate grounds. Therapy continued until 
March 2013, resulting in culture conversion in October 2011 (109). When the patient was re-
admitted in August 2013, therapy was continued with EMB, PAS, CYC, CAP, CFZ and 
amikacin (109).  
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Drug susceptibility tests (DSTs) revealed that the 2013 relapse isolate had the same drug 
resistance pattern as the initial MDR-TB isolate, except that the latest isolate was also 
resistant to CFZ. Analysis of Rv0678, explained the cause of CFZ resistance by Hartkroon et 
al. (2014) revealed that the 2011 isolate displayed a wild-type sequence, while the CFZ 
resistant isolate had a non-synonymous mutation at the second base pair, causing a 
methionine to alanine codon change (109). The observed mutation (M1A) caused the loss of 
Rv0678 expression and was regarded as the most probable cause of CFZ resistance (109).  
During another study clinical isolates with an increased BDQ post-baseline MIC were 
selected (107). The Rv0678 gene of these isolates were sequenced, and revealed mutations in 
the gene and following MIC testing the isolates displayed CFZ cross-resistance (107). 
This observation has important consequences for drug development. Currently the TB 
Alliance has three regimens in their pipeline where BDQ and CFZ are both in the same 
regimen. The cross-resistance which has recently been identified between BDQ and CFZ will 
render these regimens potentially inadequate (108, 109). This observation implies that BDQ 
therapy, for an unknown reason, could promote the development of mutations in Rv0678, 
rendering CFZ useless as a back-up therapy regimen. Although the reason for the mutational 
evolution is unclear, it was observed by others that exposure to drugs which influence energy 
metabolism genes (BDQ, azoles and CFZ), all result in mutations in Rv0678 (108, 109, 130). 
These mutations inactivate the DNA binding protein and its transcriptional regulatory 
activity, ultimately leading to increased expression of genes involved in siderophore transport 
across the cell membrane (108, 131). A further concern is that upregulation of these genes 
does not have a growth defect in vitro or in mice (107), suggesting the absence of a fitness 
cost associated with the emergence of CFZ resistance.  
5.3. Future Studies 
In order to evaluate the role of the different mutations on CFZ resistance, each gene described 
in this study should be evaluated independently. Such studies should include the generation 
of single mutants generated by targeting the individual genes. The role of Rv0678 has already 
been established in CFZ resistance from clinical isolates. However, the effect on the fitness of 
the bacterium in vivo should be explored. Such studies would help to establish if the lack of a 
fitness deficit might aid the spread of CFZ resistant drug isolates between people. In the 
future, a CFZ resistant mutant containing a non-synonymous mutation in Rv0678 should be 
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grown in iron depleted media. If the CFZ resistant isolate is less resistant to CFZ it validates 
the role of iron in CFZ resistance described in Chapter 5.1.1. 
Another way to further investigate the influence of each gene is the construction of single 
gene knockouts. Only after knocking out individual genes can the full extent of the influence 
that the gene has on CFZ resistance be determined. 
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Chapter 6 
Conclusion 
Identifying the molecular mechanisms of CFZ resistance are essential for enabling the 
development of proper diagnostic screens in patients who have multidrug resistant 
tuberculosis and require treatment with CFZ. 
During this study three novel, non-synonymous mutations were identified in CFZ resistant 
clones. Two of these resulted in premature stop codons in the respective genes, namely a 92 
bp deletion in Rv2941 and a 1 bp insertion in Rv3696c. The third mutation was located in 
Rv0678, a gene previously associated with CFZ resistance. However, the mutation we 
identified in this study had not been previously described, namely A84T (107, 108).  
Although the mutation in Rv0678 is novel, we hypothesised that this mutation was the most 
probable cause of CFZ resistance in this clone. However confirmation studies need to be 
done to verify the role of this novel mutation. We hypothesise that this mutation, like 
previously described Rv0678 mutations leads to upregulation of a specific efflux pump 
associated with siderophore transport in M. tuberculosis. More studies also need to be done to 
establish how this upregulation leads to CFZ resistance. 
The remaining two mutations have not been associated with CFZ resistance in other studies. 
However, the gene product of Rv2941, a fatty-acid-AMP ligase (FadD28), had been 
associated with the product of another gene, ppsC, of which a mutation had been described in 
a clinical CFZ resistant isolate which also contained an insertion in Rv0678 (107). Both 
FadD28 and PpsC are involved in phthiocerol dimycocerosates (PDIM) biosynthesis, which 
is known to affect the sensitivity of M. tuberculosis to antibacterial drugs. Rv2941 also has 
strong associations with other cell-wall associated proteins, thus it can be hypothesised that 
CFZ sensitivity potentially could be affected by the cell wall integrity of M. tuberculosis.  
However, studies need to be done to assess an association between PDIM biosynthesis and 
sensitivity to CFZ before conclusions can be drawn. The third mutation, a 1 bp insertion in 
Rv3696c, is not suspected to play a role in CFZ resistance, but this needs to be confirmed. 
In summary, we identified a novel mutation in a M. tuberculosis gene with a known role of 
resistance to CFZ. This work thus supports the previously described role of the Rv0678 gene 
product in CFZ resistance and suggests that this gene is a strong candidate for clinical 
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diagnostic screens to identify CFZ resistance in M. tuberculosis clinical isolates. The roles of 
the additional novel mutants in modulating CFZ resistance requires further investigation. 
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Addendum 
BACTEC
TM
 MGIT
TM
 960 Drug Concentration Equations 
(                                   )  (                )
(                        )
             
 
(                        )
(                                 )
                
 
(       )  (               
                   )
(                        )
      
*ddH2O : double distilled water 
MGIT Tube Volume: 8.4 ml 
Volume Used to Inoculate MGIT Tube: 100 µl 
Volume of ddH2O Used to Dilute Drug: 1 ml 
The final drug concentration is obtained when z ml is diluted with ddH2O to a final volume of 
1 ml. 
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